EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options - Cancer Treatment Reviews
DANUBE Trial - UROONCO Bladder Cancer
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis - European Journal of Cancer
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Is Danube Pharmaceuticals Inc. late reporting EU clinical trials?
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Management of metastatic bladder cancer - Cancer Treatment Reviews
Meeting Updates Refine Approaches Toward Urothelial Carcinoma
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? - European Urology
DANUBE Trial - UROONCO Bladder Cancer
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma - ScienceDirect
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Overview of Microbicide Clinical Trials | Download Table
AstraZeneca's Imfinzi records double bladder cancer failure, endangering first nod and dual-IO case | Fierce Pharma
AstraZeneca Bladder Cancer Treatment Fails to Hit the Mark in Phase III Trial | BioSpace
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. - ppt download
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - The Lancet ...
The Korean Journal of Internal Medicine
Continued) Key clinical trials' efficacy data of ICIs in patients with... | Download Scientific Diagram
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV
